Résumé

Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the 'one dose fits all' policy is subject to criticism. Recent findings assert the anxiety of the scientific community concerning the pharmacokinetic properties of dabigatran etexilate, that is, an important interindividual variability including an important genetic variant with a significant dependence of the renal function as route of elimination.Areas covered: This meta-opinion provides an overview of the current knowledge and evidence on the dose tailoring of dabigatran etexilate. It also discusses the remaining challenges to benefit from this perspective strategy to enhance the benefit-risk balance of dabigatran etexilate. Data were searched in the published literature and on regulatory agencies' websites. Additionally, unpublished data were searched and discussed.Expert opinion: Causality between dabigatran exposure and bleeding risk is now established and recommendations on how to best estimate the drug exposure are published. Additionally, simulating studies revealed that a dose adaptation based on dabigatran plasma concentration estimations could improve the benefit-risk profile of the drug. This accumulating evidence suggests that some patients under dabigatran etexilate may benefit from a tailoring of the dose beyond the ones already proposed by the manufacturer.

langue originaleAnglais
Pages (de - à)1283-1289
Nombre de pages7
journalExpert Opinion On Drug Safety
Volume14
Numéro de publication8
Date de mise en ligne précoce21 mai 2015
Les DOIs
étatPublié - 1 août 2015

Empreinte digitale

Expert Testimony
Dabigatran
Causality
Pharmaceutical Preparations
Anticoagulants
Thrombosis
Anxiety
Pharmacokinetics
Hemorrhage
Kidney

Citer ceci

@article{bfe29f0e1bb24041ac750cff55b143ae,
title = "Dose tailoring of dabigatran etexilate: Obvious or excessive?",
abstract = "Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the 'one dose fits all' policy is subject to criticism. Recent findings assert the anxiety of the scientific community concerning the pharmacokinetic properties of dabigatran etexilate, that is, an important interindividual variability including an important genetic variant with a significant dependence of the renal function as route of elimination.Areas covered: This meta-opinion provides an overview of the current knowledge and evidence on the dose tailoring of dabigatran etexilate. It also discusses the remaining challenges to benefit from this perspective strategy to enhance the benefit-risk balance of dabigatran etexilate. Data were searched in the published literature and on regulatory agencies' websites. Additionally, unpublished data were searched and discussed.Expert opinion: Causality between dabigatran exposure and bleeding risk is now established and recommendations on how to best estimate the drug exposure are published. Additionally, simulating studies revealed that a dose adaptation based on dabigatran plasma concentration estimations could improve the benefit-risk profile of the drug. This accumulating evidence suggests that some patients under dabigatran etexilate may benefit from a tailoring of the dose beyond the ones already proposed by the manufacturer.",
keywords = "Anticoagulant drugs, Benefit-risk assessment, Dabigatran etexilate, Drug monitoring",
author = "Jonathan Douxfils and Fran{\cc}ois Mullier and Dogn{\'e}, {Jean Michel}",
year = "2015",
month = "8",
day = "1",
doi = "10.1517/14740338.2015.1049995",
language = "English",
volume = "14",
pages = "1283--1289",
journal = "Expert Opinion On Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "8",

}

Dose tailoring of dabigatran etexilate : Obvious or excessive? / Douxfils, Jonathan; Mullier, François; Dogné, Jean Michel.

Dans: Expert Opinion On Drug Safety, Vol 14, Numéro 8, 01.08.2015, p. 1283-1289.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - Dose tailoring of dabigatran etexilate

T2 - Obvious or excessive?

AU - Douxfils, Jonathan

AU - Mullier, François

AU - Dogné, Jean Michel

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the 'one dose fits all' policy is subject to criticism. Recent findings assert the anxiety of the scientific community concerning the pharmacokinetic properties of dabigatran etexilate, that is, an important interindividual variability including an important genetic variant with a significant dependence of the renal function as route of elimination.Areas covered: This meta-opinion provides an overview of the current knowledge and evidence on the dose tailoring of dabigatran etexilate. It also discusses the remaining challenges to benefit from this perspective strategy to enhance the benefit-risk balance of dabigatran etexilate. Data were searched in the published literature and on regulatory agencies' websites. Additionally, unpublished data were searched and discussed.Expert opinion: Causality between dabigatran exposure and bleeding risk is now established and recommendations on how to best estimate the drug exposure are published. Additionally, simulating studies revealed that a dose adaptation based on dabigatran plasma concentration estimations could improve the benefit-risk profile of the drug. This accumulating evidence suggests that some patients under dabigatran etexilate may benefit from a tailoring of the dose beyond the ones already proposed by the manufacturer.

AB - Introduction: Dabigatran etexilate is used for preventing blood clots and tends to replace older anticoagulants in many of their indications. However, the 'one dose fits all' policy is subject to criticism. Recent findings assert the anxiety of the scientific community concerning the pharmacokinetic properties of dabigatran etexilate, that is, an important interindividual variability including an important genetic variant with a significant dependence of the renal function as route of elimination.Areas covered: This meta-opinion provides an overview of the current knowledge and evidence on the dose tailoring of dabigatran etexilate. It also discusses the remaining challenges to benefit from this perspective strategy to enhance the benefit-risk balance of dabigatran etexilate. Data were searched in the published literature and on regulatory agencies' websites. Additionally, unpublished data were searched and discussed.Expert opinion: Causality between dabigatran exposure and bleeding risk is now established and recommendations on how to best estimate the drug exposure are published. Additionally, simulating studies revealed that a dose adaptation based on dabigatran plasma concentration estimations could improve the benefit-risk profile of the drug. This accumulating evidence suggests that some patients under dabigatran etexilate may benefit from a tailoring of the dose beyond the ones already proposed by the manufacturer.

KW - Anticoagulant drugs

KW - Benefit-risk assessment

KW - Dabigatran etexilate

KW - Drug monitoring

UR - http://www.scopus.com/inward/record.url?scp=84937250263&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1049995

DO - 10.1517/14740338.2015.1049995

M3 - Article

VL - 14

SP - 1283

EP - 1289

JO - Expert Opinion On Drug Safety

JF - Expert Opinion On Drug Safety

SN - 1474-0338

IS - 8

ER -